benzyl (3R)-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate | 146503-35-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: benzyl (3R)-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
• 英文别名: benzyl (3R)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate；benzyl (R)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate；H-D-Tic-OBn；phenylmethyl (3R)-1,2,3, 4-tetrahydroisoquinoline-3-carboxylate
• CAS: 146503-35-7
• 化学式: C₁₇H₁₇NO₂
• 分子量: 267.327
• InChiKey: CAKWIRNQEKMHOR-MRXNPFEDSA-N

物化性质

• 沸点：
  411.6±33.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl (3R)-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 15.0h， 以90%的产率得到(R)-(+)-1,2,3,4-四氢异喹啉-3-羧酸
  参考文献：
  名称：

  Efficient Synthesis of Racemic and Enantiomerically Pure 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid and Esters

  摘要：

  在碱催化下，1,2-双（卤甲基）苯 1 a 或 b 与 2-（乙酰氨基）丙二酸二乙酯（2）发生环化反应，随后发生脱羧反应和酰胺裂解反应，制备出了外消旋和光学纯的 1,2,3,4-四氢异喹啉-3-羧酸及酯。对映体的分解是通过与(-)-薄荷醇酯化，然后柱层析分离非对映异构体混合物，或通过与扁桃酸分离苄酯的双酯盐，以及碱催化两种酯的皂化反应来实现的。

  DOI：

  10.1055/s-1992-26325
• 作为产物：
  描述：

  (R)-1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid benzyl ester; compound with toluene-4-sulfonic acid 在 碳酸氢钠 作用下， 以 乙酸乙酯 为溶剂， 生成 benzyl (3R)-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
  参考文献：
  名称：

  Facile Preparation of optically Pure (3S)- and (3R)- 1, 2, 3, 4-Tetrahydroisoquinoline-3-carboxylic Acid

  摘要：

  光学纯的(3S)-1, 2, 3, 4-四氢异喹啉-3-羧酸(1)通过对其苄基酯(2b)的分馏结晶法轻松获得，该苄基酯是由部分消旋的1盐酸盐制备而成，随后经过催化去苄基化。同样，(3R)-1也是通过相同的程序制备的。在使用光学活性的苯丙氨酸进行Pictet-Spengler反应时，通过在存在手性位移试剂的情况下，对反应产物(1)所得到的相应甲基酯(2a)进行1H核磁共振(1H-NMR)光谱分析，确定了消旋化的程度。

  DOI：

  10.1248/cpb.31.312

文献信息

• Studies on angiotensin-converting enzyme inhibitors. I. Syntheses and angiotensinconverting enzyme inhibitory activity of 2-(3-mercaptopropionyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives.
  作者：KIMIAKI HAYASHI、YASUHIKO OZAKI、KENICHI NUNAMI、TOMOFUMI UCHIDA、JYOJI KATO、KEIZO KINASHI、NAOTO YONEDA

  DOI：10.1248/cpb.31.570

  日期：——

  (3S)-2-[(2S)-3-Mercapto-2-methylpropionyl]-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid [(3S), (2S)-6a] was prepared by the reaction of (3S)-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid tert-butyl ester [(3S)-2a] or benzyl ester [(3S)-2b] with 3-benzoylthio-2-methylpropionyl chloride (3a), followed by fractional crystallization and removal of the protective group. The absolute configuration of (3S), (2S)-6a was confirmed by X-ray diffraction analysis of the thiazepino [4, 3-b] isoquinoline compound (7) derived from 6a. Resolution of 3-benzoylthio-2-methylpropionic acid (8) was completed by using optically active phenylalanine amide as a resolving agent. The other optical isomers of (3S), (2S)-6a were prepared by the reaction of (3S)- or (3R)-2b with optically active 3a. The in vitro ACE inhibitory activity of each isomer of 6a was evaluated. Among them, (3S), (2S)-6a was found to be the most potent inhibitor with an IC50 value of 8.6×10-9M. Compound (3S), (2S)-6a induced a dose-dependent inhibition of the pressor response to angiotensin I after oral administration to normotensive anesthetized rats. Moreover, (3S), (2S)-6a markedly reduced the systolic blood pressure in renal hypertensive rats (RHR) and spontaneously hypertensive rats (SHR). The in vivo ACE inhibitory activity and the hypotensive effects of (3S), (2S)-6a were comparable to those of captopril.

  (3S)-2-[(2S)-3-巯基-2-甲基丙酰基]-1, 2, 3, 4-四氢异喹啉-3-羧酸[(3S), (2S)-6a]是通过(3S)-1, 2, 3, 4-四氢异喹啉-3-羧酸叔丁基酯[(3S)-2a]或苄基酯[(3S)-2b]与3-苯甲酰硫-2-甲基丙酰氯(3a)反应制备而成，随后通过分馏结晶去除保护基团。通过对由6a衍生的噻唑烯[4, 3-b]异喹啉化合物(7)进行X射线衍射分析，确认了(3S), (2S)-6a的绝对构型。使用光学活性的苯丙氨酸酰胺作为分解剂完成了3-苯甲酰硫-2-甲基丙酸(8)的分解。通过(3S)-或(3R)-2b与光学活性3a反应制备了(3S), (2S)-6a的其他光学异构体。评估了每种6a异构体的体外ACE抑制活性。其中，(3S), (2S)-6a被发现是最有效的抑制剂，IC50值为8.6×10^-9M。化合物(3S), (2S)-6a在该显混合型麻醉大鼠口服给药后，诱导了对血管紧张素I的加压反应的剂量依赖性抑制。此外，(3S), (2S)-6a显著降低了肾性高血压大鼠(RHR)和自发性高血压大鼠(SHR)的收缩压。(3S), (2S)-6a的体内ACE抑制活性和降压效果与卡托普利相当。
• [EN] PROCESS FOR PREPARATION OF ICATIBANT ACETATE<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ACÉTATE D'ICATIBANT
  申请人：EMCURE PHARMACEUTICALS LTD

  公开号：WO2018007930A1

  公开（公告）日：2018-01-11

  The invention relates to an improved method for a 5+3+2 solution phase syntheses of Icatibant acetate (1) comprising coupling of suitably protected peptide fragments which on deprotection followed by treatment with acetic acid provide Icatibant acetate (1) having desired purity.

  这项发明涉及一种改进的方法，用于合成Icatibant醋酸盐（1）的5+3+2溶液相合成，包括耦合适当保护的肽片段，去保护后用乙酸处理，得到所需纯度的Icatibant醋酸盐（1）。
• [EN] ANTIPARASITIC TERPENE ALKALOIDS<br/>[FR] TERPENE ALCALOIDES ANTIPARASITIQUES
  申请人：PFIZER LTD

  公开号：WO2004072086A3

  公开（公告）日：2004-10-07
• SKILES, JERRY W.;WARUS, JAMES D.;SUH, JOHN T., ORG. PREP. AND PROCED. INT., 20,(1988) N 1-2, 109-115
  作者：SKILES, JERRY W.、WARUS, JAMES D.、SUH, JOHN T.

  DOI：——

  日期：——
• Facile Preparation of optically Pure (3S)- and (3R)- 1, 2, 3, 4-Tetrahydroisoquinoline-3-carboxylic Acid
  作者：KIMIAKI HAYASHI、YASUHIKO OZAKI、KENICHI NUNAMI、NAOTO YONEDA

  DOI：10.1248/cpb.31.312

  日期：——

  Optically pure (3S)-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid (1) was easily obtained by fractional crystallization of its benzyl ester (2b) p-toluenesulfonate, which was prepared from partially racemized 1 hydrochloride, followed by catalytic debenzylation. Similarly, (3R)-1 was prepared by the same procedure. The degree of racemization during the Pictet-Spengler reaction using optically active phenylalanine was determined by 1H-nuclear magnetic resonance (1H-NMR) spectroscopy of the corresponding methyl ester (2a), derived from the reaction product (1), in the presence of a chiral shift reagent.

  光学纯的(3S)-1, 2, 3, 4-四氢异喹啉-3-羧酸(1)通过对其苄基酯(2b)的分馏结晶法轻松获得，该苄基酯是由部分消旋的1盐酸盐制备而成，随后经过催化去苄基化。同样，(3R)-1也是通过相同的程序制备的。在使用光学活性的苯丙氨酸进行Pictet-Spengler反应时，通过在存在手性位移试剂的情况下，对反应产物(1)所得到的相应甲基酯(2a)进行1H核磁共振(1H-NMR)光谱分析，确定了消旋化的程度。